F9397
Flutamide
Non-steroidal anti-androgen drug
Sinónimos:
2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C11H11F3N2O3
Número CAS:
Peso molecular:
276.21
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
EC Number:
236-341-9
MDL number:
Quality level:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
Flutamide,
Quality Level
originator
Schering Plough
SMILES string
CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O
InChI
1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
InChI key
MKXKFYHWDHIYRV-UHFFFAOYSA-N
Application
Flutamide has been used to effect of testosterone on Glial cell-derived neurotrophic factor (Gdnf) mRNA production in vitro. It has also been used to study the effects of flutamide on anogenital distance and nipple retention.
Biochem/physiol Actions
Flutamide is a non-steroidal anti-androgen drug. It consists of a nitroaromatic structure. Flutamide is a potent competitor of testosterone and dihydrotestosterone receptors. It is a potent hepatotoxin.
Features and Benefits
This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 2 - Carc. 2 - Repr. 2 - STOT RE 2
target_organs
Liver
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Contenido relacionado
Product Information Sheet
Flutamide-induced hepatotoxicity: ethical and scientific issues
Giorgetti R, et al.
European Review for Medical and Pharmacological Sciences, 21(1 Suppl), 69-77 (2017)
N A Spry et al.
Prostate cancer and prostatic diseases, 16(1), 67-72 (2012-08-22)
To examine changes to whole body and regional lean mass (LM) and fat mass (FM) over 33 months of intermittent androgen suppression therapy (IAST). Phase II cohort study of 72 prostate cancer patients without metastatic bone disease. Patients received flutamide
Shuchen Gu et al.
Cellular signalling, 25(1), 66-73 (2013-01-15)
Actin cytoskeleton reorganization initiated by testosterone conjugates through activation of membrane androgen receptors (mAR) has recently been reported in colon tumor cells. This mAR-induced actin reorganization was recognized as a critical initial event, controlling apoptosis and inhibiting cell migration. The